Cutaneous lupus erythematosus in a patient undergoing intravitreal bevacizumab injections: Case report and review of the literature

Journal of Drugs in Dermatology

Volumn 12, Issue 9, 2013, Pages 1052-1055

  Cleaver, Nathan ^a   Ramirez, James ^a   Gildenberg, Stuart ^a  

^a ST JOSEPH MERCY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BEVACIZUMAB; CALCIUM; CLOBETASOL; COLECALCIFEROL; FISH OIL; PARACETAMOL; RANITIDINE; RO ANTIBODY; TRAMADOL; XANTHOPHYLL;

ADULT; ARTICLE; CASE REPORT; CENTRAL SEROUS RETINOPATHY; DEPRESSION; DRUG WITHDRAWAL; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERPIGMENTATION; MONOTHERAPY; OSTEOARTHRITIS; PHYSICAL EXAMINATION; PUNCH BIOPSY; SKIN LUPUS ERYTHEMATOSUS;

ADMINISTRATION, TOPICAL; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROID DISEASES; CLOBETASOL; FEMALE; HUMANS; INJECTIONS; KERATOSIS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MIDDLE AGED; OFF-LABEL USE; SCALP; SKIN; VITREOUS BODY;

EID: 84883390808     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Amselem et al. Papulopustular eruption after intravitreal bevacizumab. Acta Ophthalmologica. 2009; 87 (1): 110-111.
2. Avastin Prescribing Information. Genentech. [Retrieved Apr 11, 2012] http://www.gene.com/gene/products/information/oncology/avastin
3. Fourcade S et al. Localized skin necrosis of Steroid-Induced Striae Distensae: An Unusual Complication of Bevacizumab and Irinotecan therapy. Arch Dermatol. 2011 Oct; 147 (10): 1227-1228.
4. Gotlib et al. Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anti-Cancer Drugs. 2006, 17:1227-1229.
5. Gressett, Sarah and Sachin Shah. Intricacies of Bevacizumab-Induced Toxicities and Their Management. Annals of Pharmacotherapy. 2009 Mar; 43: 490-501.
6. Grisanti, Salvatore and Focke Ziemssen. Bevacizumab: Off-label use in ophthalmology. Indian J Ophthalmol. 2007 Nov-Dec; 55(6): 417-420.
7. Kabbinavar et al. Phase II, Randomized trial comparing bevacizumab plus fluorouracil/ leucovorin with FU/LV alone in patients with FU/LV alone in patients with metastatic colorectal cancer. Journal of Clinical Oncololgy. 2003 Jan; 21 (1): 60-65.
8. Keenan, Bridget and Rachel Abuav. Acneiform Eruption in a Patient Receiving Bevacizumab for Glioblastoma Multiforme. Arch Dermatol. 2010 May; 146 (5): 577.
9. Ladas et al. Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization. Clinical Ophthalmology. 2009 (3): 129-131.
10. Nguyen et al. Angiogenesis in cutaneous disease: Part I. J Am Acad Dermatol. 2009 Dec: (61) 6; 921-941.
11. Saif W, Longo W, Israel G. Correlation between rash and a positive drug response associated with Bevacizumab in a patient with advanced colorectal cancer. Clinical Colorectal Cancer. 2008 Mar; 7 (2):144-148.
12. Srivastava M et al. Drug-Induced, Ro/SSA-Positive Cutaneous Lupus Erythematosus. Arch Dermatol. 2003 Jan; 139; 45-49.
13. Sugrue MM et al. Serious wound healing complications following surgery in patients with metastatic colorectal cancer receiving bevacizumab: results of the BRITE observational cohort study. J Clin Oncol 2008; 25:4105.
14. Vano-Galvan et al. Perforating dermatosis in a patient receiving bevacizumab. J Eur Acad Dermatol Venereol. 2009 Aug; 23 (8): 972-4.
15. Vihinen et al. Cutaneous lupus erythematosus after treatment with paclitaxel and bevacizumab for metastatic breast cancer: a case report. Journal of Medical Case Reports. 2011; 5:243.
16. Wozel G, Sticherling M, Schon M. Cutaneous side effects of inhibition of VEGF signal transduction. J Ger Soc Dermatol. 2010 April; 8: 243-249.